ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
Globe Newswire•28/07/2026•06:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.